sur NanoViricides, Inc. (NASDAQ:NNVC)
NanoViricides Updates Clinical Program and Strategy
NanoViricides, Inc. (NYSE American: NNVC), a leader in broad-spectrum antiviral nanomedicines, announced an update on its NV-387 clinical program and strategy. NV-387 is their first clinical stage drug designed to mimic sulfated-proteoglycan features that many human viruses use to infect cells. Animal trials showed NV-387’s effectiveness against Influenza, COVID, RSV, and orthopoxviruses like Smallpox.
The company reported that NV-387 provided complete protection in an RSV study on lethally lung-infected mice, outperforming the current treatment, Ribavirin. This broad-spectrum efficacy suggests that viruses are unlikely to develop resistance against NV-387, unlike current medical countermeasures.
NanoViricides has completed a database audit of its Phase 1a/1b human clinical trial in India and plans to commence Phase II trials to evaluate NV-387’s effectiveness against multiple respiratory viruses under a novel adaptive trial design. Additionally, they aim to seek regulatory approvals for treating pediatric RSV disease and secure big pharma collaborations to expedite their programs.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de NanoViricides, Inc.